Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Published In:
- The New England journal of medicine, 375(4), 311-22 (2016)
- Authors:
- Marso, Steven P, Daniels, Gilbert H, Brown-Frandsen, Kirstine, Kristensen, Peter, Mann, Johannes F E, Nauck, Michael A, Nissen, Steven E, Pocock, Stuart, Poulter, Neil R, Ravn, Lasse S, Steinberg, William M, Stockner, Mette, Zinman, Bernard, Bergenstal, Richard M, Buse, John B
- Database ID:
- RPEP-03040
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03040APA
Marso, Steven P; Daniels, Gilbert H; Brown-Frandsen, Kirstine; Kristensen, Peter; Mann, Johannes F E; Nauck, Michael A; Nissen, Steven E; Pocock, Stuart; Poulter, Neil R; Ravn, Lasse S; Steinberg, William M; Stockner, Mette; Zinman, Bernard; Bergenstal, Richard M; Buse, John B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.. The New England journal of medicine, 375(4), 311-22. https://doi.org/10.1056/NEJMoa1603827
MLA
Marso, Steven P, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.." The New England journal of medicine, 2016. https://doi.org/10.1056/NEJMoa1603827
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." RPEP-03040. Retrieved from https://rethinkpeptides.com/research/marso-2016-liraglutide-and-cardiovascular-outcomes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.